Key Takeaways for Dentists Considering a DSO Sale
- A CPA-led EBITDA valuation is the essential first step. It helps set the multiple buyers apply and can reduce the risk of price cuts during due diligence.
- DSO offers usually combine cash, rollover equity, and earnouts. Modeling after-tax results for JV and holdco equity at 3, 5, 7, and 10 years can reveal the true economic value of each path.
- A structured 45–60-day auction among about 10 pre-vetted DSOs can create competitive tension that increases final sale values by up to 50% compared to a single-buyer negotiation.
- Negotiating clear LOI terms, running DSO reference checks, and comparing total economic packages (cash, equity, employment terms, and clinical autonomy) can help you find the best overall fit, not just the highest multiple.
- McLerran & Associates guides owners through valuation, auction, due diligence defense, and staff protection. Clients typically see about 30% higher valuations and an 85–90% close rate; start your confidential valuation conversation when you are ready.
Understand Your Practice Value and Paths
Step 1: Run a CPA-Led EBITDA Valuation
Every defensible DSO transaction starts with a diligence-grade EBITDA valuation, not a quick estimate from a buyer. EBITDA is the base because DSO buyers view acquisitions as investments, and the multiple applied to adjusted EBITDA drives the headline price.
In 2026, adjusted EBITDA multiples for dental practices can range from about 5× to 11× depending on practice size, hygiene mix, and associate coverage. Solo general practices with $1.2M–$2M in revenue often sell in the 5×–6.5× range. Multi-doctor practices with $2M–$4M in revenue can reach 6×–8×. Hygiene revenue above 30% of collections can add a 0.5×–1.0× premium because it signals a stable, transferable patient base.
A CPA-led valuation systematically unpacks every add-back to arrive at true adjusted EBITDA. This includes owner compensation above market rate, which inflates expenses. It also includes personal expenses run through the business, which do not reflect true operating costs. Above-market rent paid to owner-controlled real estate entities is normalized, and one-time costs that will not recur under new ownership are adjusted. An overstated adjusted EBITDA can be reduced by hundreds of thousands of dollars during a buyer’s quality-of-earnings review, which can create a seven-figure price swing at a 6× multiple.
McLerran & Associates builds this analysis remotely, pulling reports from your practice management software and cross-referencing them with your financials. The result is diligence-grade work that can hold up when buyers review your numbers.
Step 2: Model After-Tax Cash vs. JV vs. Holdco Equity at 3, 5, 7, and 10 Years
Most 2026 DSO offers are not all cash. A typical structure can include 60–75% cash at close, 15–30% mandatory rollover equity, and 5–15% earnout. Rollover equity is the portion of proceeds you keep as ownership in the DSO instead of taking as cash. That equity can sit at two levels:
- Joint-venture (JV) equity: Ownership in the specific practice or regional entity, usually with distributions and a higher floor but a lower ceiling on upside.
- Holding-company (holdco) equity: Ownership in the larger DSO platform, usually with no distributions but the potential for a higher “second bite of the apple” if the DSO later sells at a stronger valuation.
Rollover equity structured under Internal Revenue Code (IRC) sections 721 or 351 is generally not taxable at closing. Tax is usually deferred until a later liquidity event. Cash from goodwill can receive long-term capital-gains treatment at a federal top rate of 20% plus the 3.8% Net Investment Income Tax. Earnouts tied to continued employment are usually taxed as ordinary income. That difference can be significant and is worth modeling before you sign.
McLerran & Associates prepares multi-year, multi-structure financial forecasts across 3-, 5-, 7-, and 10-year horizons. These models compare real after-tax proceeds side by side so you are not relying only on headline numbers.
Step 3: Decide Doctor-to-Doctor vs. DSO Path with Side-by-Side Numbers
A $2M-revenue practice with $400K EBITDA can sell for $2.4M–$2.8M to a DSO buyer compared with $1.3M–$1.7M to a private buyer. That spread can represent a 40–80% DSO premium driven by buyer economics. Offers at the higher end of EBITDA multiples almost always include rollover equity, earnouts, and multi-year employment terms, which can reduce actual cash at close compared with the headline valuation.
Owners in the $1.5M–$3M revenue range can often pursue either a private-buyer or DSO path. McLerran & Associates works in both markets in roughly equal measure and can deliver a true side-by-side valuation. That comparison quantifies your practice’s worth in both markets so you decide with full information instead of a guess.
Get your side-by-side DSO vs. private-buyer valuation to see which path better supports your goals.
Create Competition Among Qualified DSOs
Step 4: Assemble Your Sell-Side Team and Prepare a Quality-of-Earnings Package
A quality-of-earnings (QoE) package is a formal, line-by-line bridge from your reported financials to adjusted EBITDA. Every add-back is supported by an invoice, payroll record, or similar document. Running a sell-side QoE about 6 months before going to market can help you understand the normalized EBITDA number a buyer will see and address gaps in advance. This preparation can contribute to 20–40% higher final outcomes.
Your sell-side team can include a dental-specific M&A advisor, a CPA experienced in dental deals, and a dental transactional attorney. Corporate housekeeping items to prepare include current licenses, active insurance, DEA registrations, documented HIPAA policies, and assignable employee agreements.
McLerran & Associates also prepares a Confidential Information Memorandum (CIM). This document covers practice history, services, staff, patient demographics, insurance mix, financial performance, and growth opportunities. The team then builds a virtual data room that organizes everything worth showing to buyers.
Step 5: Build a Buyer List and Run a 45–60-Day Auction
Talking to only one DSO usually means seeing only one offer, with no competitive tension to move the price. Practices taken to market through a structured multiple-buyer process can receive final sale values that average about 50% above initial unsolicited offers.
In a Q2 2026 survey, 69% of DSOs reported that their private equity sponsors expect a moderate or high increase in acquisition activity. About 78% anticipate recapitalizations within the next 12–36 months. These conditions can create real buyer competition for well-prepared practices.
McLerran & Associates runs a structured, auction-style bid process over 45–60 days among a vetted pool of qualified buyers, often generating around 10 offers per listing. DSOs known for poor post-close environments are blacklisted and do not receive invitations.
Step 6: Rank Indications of Interest and Negotiate LOI Terms
An Indication of Interest (IOI) is a non-binding preliminary offer that outlines a price range, cash-versus-rollover mix, contingencies, and timing. After ranking IOIs, the process usually moves to management presentations with top finalists before negotiating a Letter of Intent (LOI).
The LOI signing is often the most critical negotiation point in a DSO sale because sellers hold the most leverage before the letter is executed. After signing, negotiating power usually declines. Key LOI terms to address include valuation, full deal structure, earnout metrics, exclusivity window, and employment agreement duration and compensation.
Red flags at the LOI stage can include pressure to sign within 48 hours, vague claims about clinical autonomy, earnout structures where the buyer controls the inputs, and broad non-compete clauses.
Find a DSO That Fits Your Practice
Step 7: Conduct a DSO Reference Check
Up to 40% of a DSO deal can be paid in equity, which means you are effectively buying stock in the DSO. Private equity-backed DSOs often issue common equity or common-equivalent units to selling dentists while preferred investors keep liquidation preferences. In a downside exit, common equity can be worth zero even if the platform sells near its current valuation. Treating the buyer like an investment and vetting them carefully can be one of the main factors in protecting your rollover equity.
DSO Reference Check Questionnaire
| Question | Red Flag | Green Flag | Why It Matters |
|---|---|---|---|
| Is the DSO’s overall platform profitable, and is same-store revenue still growing at existing locations? | Declining same-store revenue, evasive answers about platform-level profitability | Documented same-store growth, willingness to share platform financials under NDA | Rollover equity value depends on the DSO’s performance. A struggling platform can make your retained equity far less valuable. |
| What is the private equity sponsor’s track record with dental platforms, and what is the expected hold period? | First dental investment, no prior exits, unclear timeline | Multiple prior dental exits, defined 3–7 year hold period with recapitalization history | About 78% of DSOs anticipate recapitalizations within 12–36 months. The sponsor’s exit strategy can influence when your equity may become liquid. |
| What clinical autonomy will you retain post-close, and what decisions require DSO approval? | Vague verbal assurances, no written clinical autonomy provisions in the MSA | Specific written provisions in the Management Services Agreement (MSA) defining DSO scope | Clinical autonomy can affect your production, patient care, and ability to meet earnout targets. |
| Can you speak with three to five dentists who sold to this DSO 12–36 months ago? | Refusal to provide references, only curated testimonials offered | Willingness to connect you with multiple independent sellers across different markets | Post-close seller feedback can be a reliable indicator of whether the DSO’s promises match reality. |
Step 8: Compare Final Offers on Total Economics and Autonomy
The highest headline multiple is not always the strongest offer. A $3M purchase price with a 3-year transition employment agreement at below-market compensation can be worth less than a $2.5M price with a market-rate agreement. Sellers can benefit from modeling the total economic package, including upfront proceeds, transition compensation, and the opportunity cost of below-market pay.
Compare finalists across cash at close, equity level and DSO financial health, earnout structure, employment terms, and staff retention commitments. This comparison can help you see the full picture instead of focusing on a single number.
Maximize Your Outcome and Protect Your Team
Step 9: Defend EBITDA, Close the Deal, and Protect Staff
After the LOI is signed, the buyer’s QoE team will review every add-back in your adjusted EBITDA. Aggressive or unsupported add-backs are one of the most common reasons a deal price drops during due diligence. Buyers may use these findings to “re-trade,” which means renegotiating the price downward after an agreement in principle.
McLerran & Associates provides QoE defense during this phase. The team defends the EBITDA it underwrote and reminds buyers that other vetted bidders remain available if they attempt to re-trade. The competitive auction can provide leverage that continues through closing.
Transition agreements for staff, including retention bonuses, employment continuity provisions, and clear integration timelines, can protect the goodwill you have built and reduce the risk of patient attrition that might affect earnouts.
Cash vs. JV vs. Holdco Equity Outcomes at 3, 5, 7, and 10 Years
The table below illustrates how the three main deal components can behave over time for a hypothetical $1.5M collections practice. These figures are illustrative ranges based on current market structures and should not be viewed as guaranteed results. Your CPA and M&A advisor can help you model outcomes specific to your practice.
| Structure Component | Typical 2026 Share of Deal | Tax Character and Timing | Risk and Liquidity Profile |
|---|---|---|---|
| Cash at Close (Goodwill) | 60–75% of deal value | Long-term capital gains (see Step 2 for tax rates); state tax adds about 0–13.3% | Certain and immediate, no performance risk, taxable in year of close |
| JV-Level Rollover Equity | 15–30% of deal value; distributions possible | Generally tax-deferred at close under IRC sections 721 or 351; gain usually recognized at liquidity event and often taxed at long-term capital gains rates if held more than 12 months | Higher floor due to distributions, lower ceiling, value tied to regional entity performance, typically illiquid for 3–7 years |
| Holdco Rollover Equity | 20–40% of deal value in platform-level transactions | Often tax-deferred at close; long-term capital gains at liquidity event; potential phantom income through K-1 allocations in LLC structures | No distributions, higher ceiling if the DSO exits at a premium, preferred investor rights can reduce common equity value in weaker scenarios, often illiquid for 5–10 years |
Frequently Asked Questions
How long does it take to sell a dental practice to a DSO?
The full process from initial engagement to closing typically runs 6–9 months. A 45–60-day competitive auction phase, during which McLerran & Associates solicits offers from vetted buyers, is followed by LOI negotiation and a 60–120 day due diligence period. Closing then includes regulatory notices, insurance credentialing, and lease assignments. Owners who begin preparation 12–18 months before their target close date can be in a stronger position because financial cleanup, associate agreements, and compliance documentation take time.
What is the typical rule of thumb for valuing a dental practice in 2026?
For DSO transactions, valuation usually relies on a multiple of adjusted EBITDA, not a percentage of collections. Adjusted EBITDA is calculated by recasting owner compensation to a fair-market clinical wage, removing personal expenses, and normalizing one-time costs. The multiple applied to that EBITDA can vary based on size, associate coverage, hygiene percentage, payer mix, and geography. Smaller owner-dependent practices tend to attract lower multiples, while larger associate-led or multi-location practices with less key-person risk can attract higher multiples. In doctor-to-doctor sales, a percentage of trailing-twelve-month collections remains common, although EBITDA analysis is appearing more often. Your multiple is ultimately determined by your specific numbers and the competitive market for your practice, which a diligence-grade valuation can help clarify.
What is the dentist 2-year rule, and does it apply to DSO deals?
The “2-year rule” is an informal reference to the minimum post-close employment period many DSO buyers have historically required. In 2026, many buyers have extended that minimum. A 5-year post-close employment term is increasingly common, driven by provider risk and continuity concerns. The length and terms of your employment agreement, including compensation, schedule, and autonomy, are negotiable and can affect the total economic value of the deal. A below-market employment agreement over a long term can reduce your net proceeds compared with a shorter agreement at market-rate pay. McLerran & Associates negotiates these terms as part of the LOI process.
How much can I sell my dental practice for?
Your potential sale price depends on adjusted EBITDA, buyer demand for your practice, and the structure you accept. A structured competitive auction, rather than a single-buyer negotiation, can be one of the most reliable ways to discover the true market price. McLerran & Associates clients typically receive about 30% higher valuations than owners who sell on their own, driven by the tension of multiple offers. In one documented case, a practice that received a free $2.5M valuation was valued by McLerran at $4.5M and ultimately sold for $5.25M after a competitive process. The starting point is a diligence-grade EBITDA valuation, not a buyer’s preliminary estimate.
How do I protect my staff when selling to a DSO?
Staff protection usually begins at the LOI stage. Transition agreements, retention bonuses, and employment continuity provisions can be negotiated into the definitive agreements before you grant exclusivity. McLerran & Associates evaluates buyers on financial terms and on their post-close track record with staff and has blacklisted DSOs known for poor post-close environments. The goal is a strong financial outcome paired with a buyer whose integration model supports the team you have built.
When should I delay selling my dental practice?
Delaying can make sense if your adjusted EBITDA is below the scale that attracts institutional DSO buyers, if your practice is heavily owner-dependent and you have 12–24 months to reduce that concentration through associate hiring, or if your payer mix includes significant Medicaid exposure that currently compresses multiples. McLerran & Associates can explain how your practice is positioned and, if you are not ready, can update your valuation a year later rather than push you into a deal that undervalues your work. Beginning the conversation well before you need to sell can give you time to make a deliberate decision.
Discuss your practice, timeline, and options with no obligation to proceed.
Conclusion: Run a Structured, Dentist-Focused Process
Selling a dental practice to a DSO is a 9-step competitive process, not a single conversation. It starts with a CPA-led EBITDA valuation, creates competition among vetted buyers through a structured 45–60-day auction, defends value through quality-of-earnings diligence, and ends after you compare cash, JV equity, and holdco equity outcomes across multiple offers. Owners who follow this process with professional sell-side representation can often achieve stronger prices, better terms, and more stable post-close outcomes than those who negotiate alone or with a generalist broker.
McLerran & Associates has guided owners through about 2,000 successful practice sales and more than $2 billion in closed transaction volume, with a transaction rate of about 85–90% compared with an industry norm closer to 35–40%. Clients typically receive around 30% higher valuations than they might achieve selling on their own. The firm works only on the sell side, representing the practice owner and not the buyer.
If you own a premier dental practice and are evaluating a DSO affiliation now or in the future, understanding what your practice may be worth and how the market views it can be a valuable first step. Start a confidential conversation with McLerran & Associates to explore your options. You can also reach the team at (512) 900-7989 or info@dentaltransitions.com.
